The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer.

Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings Call Transcript January 21, 2026 Johnson & Johnson reports earnings inline with ...

Apogee Therapeutics (APGE) leverages IL-13 pathway optimization to enable less frequent dosing, targeting a leadership shift ...

MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory ...

Blood lactate is influenced by a wide range of metabolic processes. Blood lactate—much like central venous pressure—can ...

Herbicide RoundupTM, announced that the controversial herbicide glyphosate would be phased out of consumer products and ...

Mare BioInnovations launchd Ocythera led by Dr. Martin Petkovich with support of Dr. Don Cameron and acting CEO Joseph ...

Johnson & Johnson ( JNJ) Q4 2025 Earnings Call January 21, 2026 8:30 AM EST Good morning, and welcome to Johnson & Johnson's Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] This ...

CNW/ - adMare BioInnovations is proud to announce the creation of Ocythera, a new biopharmaceutical company dedicated to ...

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the ...

Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...